Breaking News Instant updates and real-time market news.

BPMC

Blueprint Medicines

$75.97

-2.2 (-2.81%)

07:25
06/03/19
06/03
07:25
06/03/19
07:25

Blueprint Medicines should be bought on weakness, says Wedbush

Wedbush analyst David Nierengarten would be a buyer on Blueprint Medicines share weakness, as he feels concerns over updated NAVIGATOR data showing three intracranial hemorrhages are "likely exaggerated." There are known increase in bleeding occurrences with other kinase inhibitors, he notes. The analyst reiterates an Outperform rating and $104 price target on the stock.

  • 04

    Jun

  • 18

    Jun

BPMC Blueprint Medicines
$75.97

-2.2 (-2.81%)

03/28/19
COWN
03/28/19
NO CHANGE
COWN
Outperform
Blueprint closing gap with Loxo in RET+ tumors, says Cowen
Cowen analyst Marc Frahm said he believes the regulatory updates offered last night by Blueprint Medicines (BPMC) for avapritinib, BLU-667 and BLU-782 are all incremental positives, but he views the new clinical data for BLU-667 as "much more newsworthy." His prior survey of lung cancer physicians and investors to assess what response rate from BLU-667 they would consider competitive to Loxo Oncology's (LOXO) LOXO-292 yielded an average physician response of 59% and average investor response was 62%. Given that Blueprint reported an ORR of 62% within the second-line NSCLC cohort of 34 patients, Frahm think consensus is likely to shift towards BLU-667 capturing a meaningful share of the RET+ market, he tells investors. He keeps an Outperform rating on Blueprint Medicines.
04/03/19
MSCO
04/03/19
INITIATION
Target $112
MSCO
Overweight
Blueprint Medicines initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz initiated Blueprint Medicines with an Overweight rating and $112 price target, calling avapritinib, the company's s lead asset for the treatment of certain types of gastrointestinal stromal tumors, the key driver of his valuation. Avapritinib is on track to be submitted to the FDA in Q2, which should potentially put the drug on the market by year-end, and data so far show it to be a promising therapy, Lebowitz tells investors. He projects gastrointestinal stromal tumor revenues approaching $600M by 2026.
05/23/19
GSCO
05/23/19
INITIATION
Target $125
GSCO
Buy
Blueprint Medicines assumed with a Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter assumed coverage of Blueprint Medicines with a Buy rating and $125 price target. The firm previously had a Buy rating on the shares. The analyst recommends owning Blueprint for the near- and long-term growth outlook of its two impending launches, avapritinib for PDGFRalpha D842V mutant/4L gastrointestinal stromal tumors and BLU-667 for RET-altered non-small cell lung cancer. He assumes peak unadjusted global sales of $1.7B.
06/03/19
PIPR
06/03/19
NO CHANGE
Target $55
PIPR
Overweight
Deciphera price target raised to $55 from $50 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Deciphera Pharmaceuticals (DCPH) to $55 from $50 after hosting investor meetings with management and reviewing competitor Blueprint Medicines' (BPMC) avapritinib update over the weekend. Given the "significant" valuation-gap between the two companies, driven by misperceptions around their respective KIT inhibitors, new money investment into Deciphera "right here makes a lot of sense," Raymond tells investors in a research note. He keeps an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

PG

Procter & Gamble

06:29
10/23/19
10/23
06:29
10/23/19
06:29
Recommendations
Procter & Gamble analyst commentary  »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOW

ServiceNow

$228.26

-12.315 (-5.12%)

06:29
10/23/19
10/23
06:29
10/23/19
06:29
Recommendations
ServiceNow analyst commentary  »

ServiceNow stock price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 09

    Dec

  • 12

    Dec

CADE

Cadence Bancorp

$17.95

0.24 (1.36%)

06:29
10/23/19
10/23
06:29
10/23/19
06:29
Earnings
Cadence Bancorp reports Q3 EPS 34c, consensus 49c »

Reports Q3 revenue $,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

LLY

Eli Lilly

$110.00

2.06 (1.91%)

06:29
10/23/19
10/23
06:29
10/23/19
06:29
Earnings
Eli Lilly reports Q3 EPS $1.48, consensus $1.40 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 28

    Oct

PZZA

Papa John's

$57.02

0.43 (0.76%)

06:28
10/23/19
10/23
06:28
10/23/19
06:28
Initiation
Papa John's initiated  »

Papa John's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 13

    Nov

  • 11

    Dec

TXN

Texas Instruments

$128.61

-2.32 (-1.77%)

06:25
10/23/19
10/23
06:25
10/23/19
06:25
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNE

Veoneer

$16.59

-0.18 (-1.07%)

06:24
10/23/19
10/23
06:24
10/23/19
06:24
Earnings
Breaking Earnings news story on Veoneer »

Veoneer sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 29

    Oct

  • 09

    Dec

VNE

Veoneer

$16.59

-0.18 (-1.07%)

06:23
10/23/19
10/23
06:23
10/23/19
06:23
Earnings
Veoneer reports Q3 EPS ($1.20), consensus ($1.34) »

Reports Q3 revenue $462M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 29

    Oct

  • 09

    Dec

UAA

Under Armour

$21.38

1.29 (6.42%)

, UA

Under Armour

$19.42

1.25 (6.88%)

06:22
10/23/19
10/23
06:22
10/23/19
06:22
Recommendations
Under Armour, Under Armour analyst commentary  »

CEO change positive for…

UAA

Under Armour

$21.38

1.29 (6.42%)

UA

Under Armour

$19.42

1.25 (6.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

  • 04

    Nov

AAPL

Apple

$239.97

-0.52 (-0.22%)

06:19
10/23/19
10/23
06:19
10/23/19
06:19
Periodicals
Apple to shorten Japan Display's payment periods, Reuters reports »

Apple plans to help out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

ANTM

Anthem

$260.28

7.12 (2.81%)

06:19
10/23/19
10/23
06:19
10/23/19
06:19
Earnings
Anthem raises FY19 operating revenue view to approximately $103B from $102B 

FY19 consensus $101.87B.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

VZ

Verizon

$60.80

0.06 (0.10%)

, SAP

SAP

$131.78

-0.91 (-0.69%)

06:18
10/23/19
10/23
06:18
10/23/19
06:18
Hot Stocks
Verizon and SAP co-developing Internet of Things analytics solutions »

Verizon VZ) and SAP (SAP)…

VZ

Verizon

$60.80

0.06 (0.10%)

SAP

SAP

$131.78

-0.91 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 26

    Oct

  • 19

    Nov

  • 09

    Dec

ANTM

Anthem

$260.28

7.12 (2.81%)

06:17
10/23/19
10/23
06:17
10/23/19
06:17
Hot Stocks
Anthem raises FY19 operating cash flow view to greater than $5.5B »

Prior view was greater…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CMG

Chipotle

$831.69

-20.195 (-2.37%)

06:17
10/23/19
10/23
06:17
10/23/19
06:17
Recommendations
Chipotle analyst commentary  »

Chipotle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HCM

Hutchison China MediTech

$20.33

0.27 (1.35%)

06:17
10/23/19
10/23
06:17
10/23/19
06:17
Initiation
Hutchison China MediTech initiated  »

Hutchison China MediTech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPL

PPL Corp.

$32.74

0.09 (0.28%)

06:15
10/23/19
10/23
06:15
10/23/19
06:15
Upgrade
PPL Corp. rating change  »

PPL Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

MNOV

MediciNova

$7.94

-0.235 (-2.88%)

06:15
10/23/19
10/23
06:15
10/23/19
06:15
Hot Stocks
MediciNova receives notice of allowance for new patent covering MN-001 »

MediciNova announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$14.00

-0.58 (-3.98%)

06:14
10/23/19
10/23
06:14
10/23/19
06:14
Recommendations
Snap analyst commentary  »

Barclays ups Snap target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

EVR

Evercore Partners

$78.99

0.22 (0.28%)

06:13
10/23/19
10/23
06:13
10/23/19
06:13
Earnings
Evercore Partners reports Q3 adjusted EPS $1.26, consensus $1.63 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

FCFS

First Cash Financial

$94.76

-0.19 (-0.20%)

06:13
10/23/19
10/23
06:13
10/23/19
06:13
Hot Stocks
First Cash Financial raises quarterly dividend 8% to 27c from 25c per share »

To be paid on November 29…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

NSANY

Nissan

$0.00

(0.00%)

06:12
10/23/19
10/23
06:12
10/23/19
06:12
Periodicals
Nissan set to axe Datsun brand, drop unprofitable products, Reuters reports »

Nissan is likely to kill…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCFS

First Cash Financial

$94.76

-0.19 (-0.20%)

06:12
10/23/19
10/23
06:12
10/23/19
06:12
Earnings
First Cash Financial backs FY19 adjusted EPS view $3.85-$4.00 

FY19 consensus $3.90.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

LBRT

Liberty Oilfield Services

$8.74

0.07 (0.81%)

06:12
10/23/19
10/23
06:12
10/23/19
06:12
Initiation
Liberty Oilfield Services initiated  »

Liberty Oilfield Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

CE

Celanese

$119.23

-2.145 (-1.77%)

06:11
10/23/19
10/23
06:11
10/23/19
06:11
Recommendations
Celanese analyst commentary  »

Celanese price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HLT

Hilton

$90.81

-1.57 (-1.70%)

06:11
10/23/19
10/23
06:11
10/23/19
06:11
Earnings
Hilton sees Q4 adjusted EPS 91c-96c, consensus 99c »

Sees Q4 management and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.